Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
AbstractChiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains. This review exemplifies the various studies made to investigate the effect of chirality on the antiretroviral activity of top HIV-1 NNRTI compounds, such as nevirapine (NVP), efavirenz (EFV), alkynyl- and alkenylquinazolinone DuPont compounds (DPC), diarylpyrimidine (DAPY), dihydroalkyloxybenzyloxopyrimidine (DABO), phenethylthiazolylthiourea (PETT), indolylarylsulfone (IAS), arylphosphoindole (API) and trifluoromethylated indole (TFMI) The chiral separation, the enantiosynthesis, along with the biological properties of these HIV-1 NNRTIs, are discussed. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Famiglini, V.; Silvestri, R. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Molecules 2016, 21, 221.
Famiglini V, Silvestri R. Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Molecules. 2016; 21(2):221.Chicago/Turabian Style
Famiglini, Valeria; Silvestri, Romano. 2016. "Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors." Molecules 21, no. 2: 221.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.